In summary, these data identify REV-ERB as a pharmacological target to downregulate the NLRP3 inflammasome, and possibly additional adverse immune responses, for mitigating MI reperfusion injury and preventing HF. This evidence concerns the gene NLRP3 and myocardial infarction.